Literature DB >> 30607868

Machine learning-based radiomic models to predict intensity-modulated radiation therapy response, Gleason score and stage in prostate cancer.

Hamid Abdollahi1, Bahram Mofid2, Isaac Shiri3,4, Abolfazl Razzaghdoust5, Afshin Saadipoor2, Arash Mahdavi6, Hassan Maleki Galandooz7, Seied Rabi Mahdavi8,9.   

Abstract

OBJECTIVE: To develop different radiomic models based on the magnetic resonance imaging (MRI) radiomic features and machine learning methods to predict early intensity-modulated radiation therapy (IMRT) response, Gleason scores (GS) and prostate cancer (Pca) stages.
METHODS: Thirty-three Pca patients were included. All patients underwent pre- and post-IMRT T2-weighted (T2 W) and apparent diffusing coefficient (ADC) MRI. IMRT response was calculated in terms of changes in the ADC value, and patients were divided as responders and non-responders. A wide range of radiomic features from different feature sets were extracted from all T2 W and ADC images. Univariate radiomic analysis was performed to find highly correlated radiomic features with IMRT response, and a paired t test was used to find significant features between responders and non-responders. To find high predictive radiomic models, tenfold cross-validation as the criterion for feature selection and classification was applied on the pre-, post- and delta IMRT radiomic features, and area under the curve (AUC) of receiver operating characteristics was calculated as model performance value.
RESULTS: Of 33 patients, 15 patients (45%) were found as responders. Univariate analysis showed 20 highly correlated radiomic features with IMRT response (20 ADC and 20 T2). Two and fifteen T2 and ADC radiomic features were found as significant (P-value ≤ 0.05) features between responders and non-responders, respectively. Several cross-combined predictive radiomic models were obtained, and post-T2 radiomic models were found as high predictive models (AUC 0.632) followed by pre-ADC (AUC 0.626) and pre-T2 (AUC 0.61). For GS prediction, T2 W radiomic models were found as more predictive (mean AUC 0.739) rather than ADC models (mean AUC 0.70), while for stage prediction, ADC models had higher prediction performance (mean AUC 0.675).
CONCLUSIONS: Radiomic models developed by MR image features and machine learning approaches are noninvasive and easy methods for personalized prostate cancer diagnosis and therapy.

Entities:  

Keywords:  IMRT; MRI; Prediction; Prostate cancer; Radiomics

Mesh:

Year:  2019        PMID: 30607868     DOI: 10.1007/s11547-018-0966-4

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  24 in total

1.  CT imaging markers to improve radiation toxicity prediction in prostate cancer radiotherapy by stacking regression algorithm.

Authors:  Shayan Mostafaei; Hamid Abdollahi; Shiva Kazempour Dehkordi; Isaac Shiri; Abolfazl Razzaghdoust; Seyed Hamid Zoljalali Moghaddam; Afshin Saadipoor; Fereshteh Koosha; Susan Cheraghi; Seied Rabi Mahdavi
Journal:  Radiol Med       Date:  2019-09-24       Impact factor: 3.469

Review 2.  Current and future applications of machine and deep learning in urology: a review of the literature on urolithiasis, renal cell carcinoma, and bladder and prostate cancer.

Authors:  Rodrigo Suarez-Ibarrola; Simon Hein; Gerd Reis; Christian Gratzke; Arkadiusz Miernik
Journal:  World J Urol       Date:  2019-11-05       Impact factor: 4.226

Review 3.  The role of radiomics in prostate cancer radiotherapy.

Authors:  Rodrigo Delgadillo; John C Ford; Matthew C Abramowitz; Alan Dal Pra; Alan Pollack; Radka Stoyanova
Journal:  Strahlenther Onkol       Date:  2020-08-21       Impact factor: 3.621

4.  Evaluating Focal 18F-FDG Uptake in Thyroid Gland with Radiomics.

Authors:  Ayşegül Aksu; Nazlı Pınar Karahan Şen; Emine Acar; Gamze Çapa Kaya
Journal:  Nucl Med Mol Imaging       Date:  2020-07-28

5.  Delta radiomics: a systematic review.

Authors:  Valerio Nardone; Alfonso Reginelli; Roberta Grassi; Luca Boldrini; Giovanna Vacca; Emma D'Ippolito; Salvatore Annunziata; Alessandra Farchione; Maria Paola Belfiore; Isacco Desideri; Salvatore Cappabianca
Journal:  Radiol Med       Date:  2021-12-04       Impact factor: 3.469

6.  Polarization imaging-based radiomics approach for the staging of liver fibrosis.

Authors:  Yue Yao; Fengdi Zhang; Bin Wang; Jiachen Wan; Lu Si; Yang Dong; Yuanhuan Zhu; Xiaolong Liu; Lihong Chen; Hui Ma
Journal:  Biomed Opt Express       Date:  2022-02-18       Impact factor: 3.732

7.  Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.

Authors:  Isaac Shiri; Hasan Maleki; Ghasem Hajianfar; Hamid Abdollahi; Saeed Ashrafinia; Mathieu Hatt; Habib Zaidi; Mehrdad Oveisi; Arman Rahmim
Journal:  Mol Imaging Biol       Date:  2020-08       Impact factor: 3.488

8.  Value of MRI texture analysis for predicting new Gleason grade group.

Authors:  Xiaojing He; Hui Xiong; Haiping Zhang; Xinjie Liu; Jun Zhou; Dajing Guo
Journal:  Br J Radiol       Date:  2021-03-11       Impact factor: 3.039

Review 9.  Advanced analytics and artificial intelligence in gastrointestinal cancer: a systematic review of radiomics predicting response to treatment.

Authors:  Nina J Wesdorp; Tessa Hellingman; Elise P Jansma; Jan-Hein T M van Waesberghe; Ronald Boellaard; Cornelis J A Punt; Joost Huiskens; Geert Kazemier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-12-16       Impact factor: 9.236

Review 10.  Dynamic contrast-enhanced (DCE) imaging: state of the art and applications in whole-body imaging.

Authors:  Domenico Albano; Federico Bruno; Andrea Agostini; Salvatore Alessio Angileri; Massimo Benenati; Giulia Bicchierai; Michaela Cellina; Vito Chianca; Diletta Cozzi; Ginevra Danti; Federica De Muzio; Letizia Di Meglio; Francesco Gentili; Giuliana Giacobbe; Giulia Grazzini; Irene Grazzini; Pasquale Guerriero; Carmelo Messina; Giuseppe Micci; Pierpaolo Palumbo; Maria Paola Rocco; Roberto Grassi; Vittorio Miele; Antonio Barile
Journal:  Jpn J Radiol       Date:  2021-12-24       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.